Clinical trial

A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.

NCT01843127

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2013-04-01

PhasePHASE1

Study timeline

Study start (unknown)2013-04-01Date precision: month

Registry last updated2014-03-31

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetes Mellitusunresolved

Interventions

RanolazineDRUG · verified · RxNorm: ranolazine

PlaceboDRUG

ExenatideDRUG · verified · RxNorm: exenatide

Sponsors & collaborators

Gilead Scienceslead sponsor

Mapped research locations

MiamiFlorida, United States1 OrlandoFlorida, United States1 Chula VistaCalifornia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01843127 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.